Breaking Down Barriers to Obesity Care
How targeted outreach and heightened engagement can help companies achieve better outcomes
GLP-1s Alone Are Not the Answer to America’s Obesity and Chronic Illness Crises
Obesity/overweight is a significant causal factor in chronic illness and cancer. Weight loss can help people with obesity/overweight avoid and/or manage chronic illness. GLP-1s cause weight loss. So, are GLP-1s the answer to America’s obesity and chronic illness crises? Not if we overlook a key problem at the heart of both challenges: lack of access to nutritious food in the land of plenty.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Build My Health Webinar Highlights New Age for Physician Practices with Rise of GLP1 Drugs for Obesity
In a webinar last week, BuildMyHealth CEO and Co-founder Dr. Jonathan Kaplan shared how physician practices not only can access the weight loss drug by working with compounding pharmacies, but also use BuildMyHealth to provide this drug to their own patients who are suitable candidates for the drug.
Let’s Make This the Last World Obesity Care Week
By eliminating the term "obesity" in favor of person-centric language, we pave the way for a more equitable healthcare system that prioritizes the well-being of all individuals, regardless of their size or shape.
Novo Nordisk Obesity Pill Flashes the Potential to Beat Wegovy in Weight Loss
Novo Nordisk reported its weight loss pill amycretin led to greater weight loss measured at 12 weeks compared to clinical trial results for its blockbuster obesity drug Wegovy. But these results are from a small Phase 1 study and more testing is needed.
How Food-as-Medicine Execs Are Responding to Kellogg CEO’s ‘Let Them Eat Flakes’ Remarks
Kellogg CEO Gary Pilnick recently encouraged families struggling to put food on the table to turn to cereal as their go-to dinner option. Food-as-medicine executives are none too thrilled about his comments — they argue that the remarks underscore the dire need to increase public education about affordable, healthy meal planning.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
MedCity Pivot Podcast: A Conversation with Lumen CEO Daniel Tal Mor
In this episode, the CEO of Lumen talks about the sleek consumer device and why he is at a b-to-b healthcare conference.
Viking Therapeutics Obesity Drug’s Data Raise Best-in-Class Expectations
The weight loss achieved by Viking Therapeutics’ obesity drug tops results posted by Eli Lilly’s Zepbound in its pivotal test. But Viking still needs to show its results can hold up in a larger Phase 3 clinical trial.
Lose Fat, Not Muscle: Next Test for Lilly’s Zepbound Pairs It With BioAge Drug
In preclinical testing, combining BioAge Labs’ experimental drug with Eli Lilly weight drug Zepbound led to greater weight loss compared with Zepbound alone. Now the company plans to run a Phase 2 study to see if it can replicate those results in humans.
Omada Expands GLP-1 Care Track To Include Exercise Plans, Member Level Reporting
Omada's newly expanded GLP-1 Care Track provides tailored exercise plans, support for getting off of GLP-1s and calorie tracking. It also offers insight into who is responding to GLP-1s and who is engaging in Omada's program.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Novo Holdings Bolsters GLP-1 Production Capacity With $16.5B Catalent Buyout
After Novo Holdings acquires Catalent, it will sell three of the contract manufacturing giant’s sites to Novo Nordisk. Those facilities already make Novo Nordisk’s GLP-1 drugs for metabolic conditions, and they will help the company meet projected demand for these products in years to come.
Metabolic Disorder-Focused Fractyl Health ‘GUTS’ Out a $110 Million IPO
Fractyl Health will use the IPO proceeds for pivotal testing of a medical device and surgical procedure intended to address root causes of diabetes and obesity. The Fractyl pipeline also includes a gene therapy for these conditions.
We’ve Actually Treated Tens of Thousands of People on Ozempic to Date – Here’s What Really Happens and What It Likely Means for Solving Our Obesity Epidemic
We and our collective organizations’ providers have treated 10,000’s of Americans, who suffer from obesity and/or Type 2 diabetes with GLP-1 drugs. And we believe we have important observations to share.
How Are Payers Approaching Obesity Management?
GLP-1s continue to be in high demand, and the healthcare industry is watching closely to see how payers decide to cover the drugs going forward. During a virtual panel, payer executives noted that it's important to remember that GLP-1s won’t be able to solve the country’s obesity crisis by themselves.
The Prohibitive Economics of Weight Care
How we discuss overweight and obese diagnoses and how we treat those patients is slowly starting to improve. However, there’s still a lot of work to be done – in how we manufacture, market, and manage life-changing weight care medications, as well as how we expand access and improve adherence to them.